-
HLB Appoints Kim Dong-gun as CEO of U.S. Subsidiary Elevar TherapeuticsBig Tech 2026. 1. 30. 01:11반응형
Kim Dong-gun, new CEO of Elevar Therapeutics. (Photo courtesy of HLB) HLB has appointed Kim Dong-gun, head of HLB US, as chief executive officer of its U.S. subsidiary Elevar Therapeutics.
As CEO of Elevar Therapeutics, he will lead FDA regulatory strategies and commercialization efforts. He will also continue to serve as head of HLB US and chief executive officer of Immunomic Therapeutics, overseeing HLB’s U.S. operations.
IT Times: https://www.ittimes.com/news/articleView.html?idxno=82995HLB Appoints Kim Dong-gun as CEO of U.S. Subsidiary Elevar Therapeutics - IT타임스
HLB has appointed Kim Dong-gun, head of HLB US, as chief executive officer of its U.S. subsidiary Elevar Therapeutics, the company said on Jan. 29.The leadership change follows the completion of Ne...
www.ittimes.com
반응형'Big Tech' 카테고리의 다른 글
LG화학, 작년 영업이익 1조1809억… 전년비 35%↑ (0) 2026.01.30 HLB, 간암 신약 FDA 본심사 돌입… 7월 내 승인 여부 결정 (0) 2026.01.30 포스코홀딩스, 작년 영업이익 1.8조… 철강·LNG로 실적 방어 (0) 2026.01.29 삼성바이오로직스, ESG 글로벌 상위 1%… 에코바디스 플래티넘 획득 (0) 2026.01.29 쿠팡 PB 생리대 99원… 최저가 상품 보급 확대 (0) 2026.01.29